Global Information
회사소개 | 문의 | 위시리스트

중국의 우로키나아제 시장

Investigation Report on China´s Urokinase Market, 2019-2023

리서치사 China Research and Intelligence
발행일 2019년 08월 상품 코드 337515
페이지 정보 영문 30 Pages
가격
US $ 2,200 ₩ 2,602,000 Unprintable PDF (Single User License)
US $ 3,300 ₩ 3,903,000 Printable & Editable PDF (Enterprisewide License)


중국의 우로키나아제 시장 Investigation Report on China´s Urokinase Market, 2019-2023
발행일 : 2019년 08월 페이지 정보 : 영문 30 Pages

중국의 우로키나아제(Urokinase) 특허 및 승인 상황, 판매액·판매량의 추이와 예측(과거·향후 5년간), 가격 동향, 주요 제약회사와 시장 점유율, 경쟁 환경과 전망, 주요 제조업체의 개요 등을 정리하여 전해드립니다.

제1장 우로키나아제의 관련 개념

  • 우로키나아제의 효능
  • 중국 우로키나아제 시장의 동향
  • 중국에서 우로키나아제의 특허 취득·정부 인증 동향

제2장 중국내 우로키나아제 판매 동향

  • 우로키나아제 판매액
  • 우로키나아제 판매량
  • 우로키나아제 판매량 : 제형별(과거 5년간)

제3장 중국의 주요 우로키나아제 제조업체 분석

  • 주요 제조업체의 시장 점유율 분석
  • Nanjing Nanda Pharmaceutical Co., Ltd.
  • Tianjin Biochemical Pharmaceutical Co., Ltd.
  • Livzon Pharmaceutical Factory of Livzon Group
  • Wuhan Humanwell Pharmaceutical Co., Ltd.
  • Shandong PKU High-tech Huatai Pharmaceutical Co., Ltd.

제4장 중국내 우로키나아제 가격

  • Nanjing Nanda Pharmaceutical Co., Ltd.
  • Tianjin Biochemical Pharmaceutical Co., Ltd.
  • Livzon Pharmaceutical Factory of Livzon Group
  • Wuhan Humanwell Pharmaceutical Co., Ltd.
  • Shandong PKU High-tech Huatai Pharmaceutical Co., Ltd.

제5장 중국의 우로키나아제 시장 전망

  • 중국의 우로키나아제 시장을 좌우하는 요인
    • 시장 성장 촉진요인과 시장 기회
    • 위협과 과제
  • 시장 규모 예측(향후 5년간)
  • 시장 동향 예측
KSA 19.08.27

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Description

Thrombolytic therapy is using drugs to dissolve thrombi and achieve revascularization so that the brain tissue of the blocked vascular perfusion area can regain blood oxygen. As fibrin is an important composition of thrombus, current thrombolytic therapy mainly use drugs such as Streptokinase, Urokinase and Tissue Plasminogen Activator (t-PA) to dissolve fibrin.

Thrombolytic drugs include three generations. The first generation is non-specific plasminogen activators such as Streptokinase and Urokinase; the second generation is represented by t-PA such as Alteplase and Prourokinase; the third generation includes Reteplase, Tenecteplase, Nateplase, Recombinant Human Urokinase, etc.

Although Urokinase is a thrombolytic drug of the first generation, it is widely used in China. It is an enzyme protein isolated from healthy human urine or cultured from human kidney tissue.

Urokinase acts directly on the endogenous fibrinolytic system. It can catalyze the cracking of plasminogen to plasmin which dissolves thrombi by degrading fibrin clots as well as the fibrinogen, coagulation factors V and VIII in blood circulation. With a rapid onset and good effect on newly formed thrombi, Urokinase can also increase the vascular enzymatic activity of adenosine diphosphate (ADP), inhibit ADP-induced platelet aggregation and prevent thrombosis. After intravenous infusion, the activity of plasmin in the patient will be significantly increased; after a few hours of drug withdrawal, the activity of plasmin will be restored. As a traditional thrombolytic drug that has been marketed in China for many areas, Urokinase is widely used to treat acute myocardial infarction, cerebral thrombosis, pulmonary vein thrombosis, lower extremity vein thrombosis and other forms of vascular thrombosis.

Economic development, aging population and unhealthy diet push up the incidence of thrombotic diseases in China, which boosts the demand for Urokinase. According to CRI's market survey, in 2017, the sales value of Urokinase in China reached CNY 50.56 million, representing a CAGR of 7.90% from 2013 to 2017. The Urokinase by Nanjing Nanda Pharmaceutical Co., Ltd. took up the largest market share in China. Its market share was about 50.60% by sales value and about 38.50% by sales volume.

It is expected that the market size of Urokinase in China will continue to grow in the next few years.

Topics covered:

  • Market size of Urokinase in China
  • Competitive landscape of China's Urokinase market
  • Prices of Urokinase in China
  • Favorable and unfavorable factors influencing China's Urokinase market
  • Prospect of China's Urokinase market

Table of Contents

1 Relevant Concepts of Urokinase

  • 1.1 Indications for Urokinase
  • 1.2 Development of Urokinase in China
  • 1.3 Patents and Government Approval on Urokinase in China

2 Sales of Urokinase in China, 2013-2017

  • 2.1 Sales Value of Urokinase
  • 2.2 Sales Volume of Urokinase
  • 2.3 Sales of Urokinase by Dosage Form in China, 2013-2017

3 Analysis on Major Urokinase Manufacturers in China, 2013-2017

  • 3.1 Analysis on Market Share of Major Urokinase Manufacturers
  • 3.2 Nanjing Nanda Pharmaceutical Co., Ltd.
  • 3.3 Tianjin Biochemical Pharmaceutical Co., Ltd.
  • 3.4 Livzon Pharmaceutical Factory of Livzon Group
  • 3.5 Wuhan Humanwell Pharmaceutical Co., Ltd.
  • 3.6 Shandong PKU High-tech Huatai Pharmaceutical Co., Ltd.

4 Prices of Urokinase in China, 2017-2018

  • 4.1 Nanjing Nanda Pharmaceutical Co., Ltd.
  • 4.2 Tianjin Biochemical Pharmaceutical Co., Ltd.
  • 4.3 Livzon Pharmaceutical Factory of Livzon Group
  • 4.4 Wuhan Humanwell Pharmaceutical Co., Ltd.
  • 4.5 Shandong PKU High-tech Huatai Pharmaceutical Co., Ltd.

5 Prospect of China's Urokinase Market, 2019-2023

  • 5.1 Factors Influencing China's Urokinase Market
    • 5.1.1 Driving Forces and Market Opportunities
    • 5.1.2 Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

Selected Charts

  • Chart Sales of Urokinase in China, 2013-2017
  • Chart Sales Value of Urokinase in Parts of China, 2013-2017
  • Chart Sales Volume of Urokinase in China, 2013-2017
  • Chart Sales Volume of Urokinase in Parts of China, 2013-2017
  • Chart Sales Value of Urokinase Injections in China, 2013-2017
  • Chart Sales Volume of Urokinase Injections in China, 2013-2017
  • Chart Market Share of Top 5 Urokinase Manufacturers by Sales Value in China, 2013-2017
  • Chart Market Share of Top 5 Urokinase Manufacturers by Sales Volume in China, 2013-2017
  • Chart Sales Value of Urokinase by Nanjing Nanda Pharmaceutical Co., Ltd., 2013-2017
  • Chart Sales Volume of Urokinase by Nanjing Nanda Pharmaceutical Co., Ltd., 2013-2017
  • Chart Sales Value of Urokinase by Livzon Pharmaceutical Factory of Livzon Group, 2013-2017
  • Chart Sales Value of Urokinase by Wuhan Humanwell Pharmaceutical Co., Ltd., 2013-2017
  • Chart Sales Value of Urokinase by Shandong PKU High-tech Huatai Pharmaceutical Co., Ltd., 2013-2017
  • Chart Prices of Urokinase by Nanjing Nanda Pharmaceutical Co., Ltd. in Parts of China, 2017-2018
  • Chart Prices of Urokinase by Tianjin Biochemical Pharmaceutical Co., Ltd. in Parts of China, 2017-2018
  • Chart Prices of Urokinase by Livzon Pharmaceutical Factory of Livzon Group in Parts of China, 2017
Back to Top
전화 문의
F A Q